NCT02296879View on ClinicalTrials.gov

A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

March 15, 2017

Study Completion Date

June 20, 2017

Conditions
Solid Tumors
Interventions
GENETIC

SAIT301

The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Young Suk Park

OTHER

NCT02296879 - A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types | Biotech Hunter | Biotech Hunter